Walling, David P.
Shinde, Sunita N.
Pogoda, Janice M.
Kharidia, Jahnavi
Laffont, Celine M. http://orcid.org/0000-0001-8345-5980
Clinical trials referenced in this document:
Documents that mention this clinical trial
An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients
https://doi.org/10.1007/s40261-024-01347-1
Funding for this research was provided by:
Indivior
Article History
Accepted: 22 January 2024
First Online: 22 February 2024
Declarations
:
: This study was funded by Indivior Inc., North Chesterfield, VA.
: SNS, JMP, and CLM are employees of Indivior. JK was an Indivior employee at the time of the study. DPW reports grants from AbbVie, Acadia, Alkermes, Allergan, Avanir, Biogen Boehringer Ingelheim, Cerevel, CoMentis, Intra-Cellular Therapies, Indivior, Janssen, Johnson & Johnson PRD, Lundbeck, Lupin, Merck, Novartis, Noven, Otsuka, Prothena, Pfizer, Roche, Sunovion, and Takeda and personal fees from Janssen, Otsuka, Boehringer Ingelheim, Biogen Merck, and Lyndra.
: Data are available from the authors upon reasonable request. All requests for raw and analyzed data will be promptly reviewed by the sponsor delegate to verify if the request is subject to any confidentiality obligations. Patient-related data not included in the paper were generated as part of clinical trials and may be subject to patient confidentiality. Any data that can be shared will be released via a data use agreement.
: The study was approved by the local ethics committee on 18 June 2019 and was registered at ClinicalTrials.gov (identifier: NCT03978832).
: SNS, JMP, JK, and CLM contributed to the study design and data analysis. DPW conducted the study. All authors were involved in the interpretation of the data and critically reviewed the manuscript.
: All participants provided written informed consent before screening procedures.
: Not applicable.
: Not applicable.